The effect may depend on the subtype and age of the patients, as the BTK inhibitor ibrutinib plus R‐CHOP seems to improve event‐free survival and overall survival in younger patients (<60 years of age) with the ABC subtype [7]. Here, BTK is linked to aneurysmal bone cyst.